Ampio Pharmaceuticals, Inc. announced the start of construction of its new manufacturing facility for its drug candidate, Ampion(TM), for the treatment of patients afflicted with osteoarthritis of the knee. Located in the Denver Metro area, the facility is expected to be ready for production of Ampion(TM) in the summer of 2014 and should generate approximately 40 new jobs in the next two years.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.09 USD | -80.00% |
|
-10.00% | -95.61% |
15/04 | Ampio Pharmaceuticals, Inc.(NYSEAM:AMPE) dropped from S&P TMI Index | CI |
27/03 | Ampio Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-95.61% | 102K | |
+20.03% | 126B | |
+23.61% | 118B | |
+23.26% | 27.87B | |
-18.07% | 20.95B | |
-15.13% | 16.92B | |
-14.81% | 16.18B | |
+9.78% | 14.84B | |
-46.10% | 14.79B | |
+52.34% | 14.08B |
- Stock Market
- Equities
- AMPE Stock
- News Ampio Pharmaceuticals, Inc.
- Ampio Pharmaceuticals, Inc. Announces Start of Construction of its New Manufacturing Facility